Articles tagged "Rapamycin"

2015 American Transplant Congress
Delayed Tacrolimus (TAC) to Rapamycin (RAPA) Conversion in Renal Transplant Recipients With DGF/SGF
A. Haririan,¹ D. Klassen,¹ M. Keshtkar,¹ C. Drachenberg,² T. Dowling,³ E. Ramos,¹ R. Ugarte,¹ C. Cangro,¹ M. Weir.¹
¹Medicine, University of Maryland, Baltimore, MD; ²Pathology, University of Maryland, Baltimore, MD; ³Pharmacy, University of Maryland, Baltimore, MD.
The role of conversion from TAC to RAPA early after kidney transplantation in patients with DGF/SGF in improving graft function and delaying chronic allograft dysfunction…
2015 American Transplant Congress
mTOR-Based CNI Minimization Vs Withdrawal in African American Kidney Transplant Recipients
J. Fleming,¹ D. Taber,² N. Pilch,¹ H. Meadows,¹ C. Mardis,¹ J. McGillicuddy,² S. Nadig,² K. Chavin,² P. Baliga,² C. Bratton.²
¹Pharmacy, Medical University of South Carolina, Charleston, SC; ²Surgery, Medical University of South Carolina, Charleston, SC.
The purpose of this study was to compare mTOR-based CNI withdrawal vs. minimization in African American (AA) kidney transplant (KTx) recipients.METHODS: This was a single-center,…
2015 American Transplant Congress
Calcineurin Inhibitor-Free Immunossupresion After Kidney Transplantation, Using Everolimus De Novo – Single Center Experience
M. Stronka, Z. Adamska, L. Cichanska, J. Kubiak, M. Gamrat, M. Karczewski.
Department of Transplantology, General, Vascular and Plastic Surgery, Clinical Hospital of Poznan University of Medical Sciences, Poznan, Poland.
The aim of the study was to analyse the clinical outcome in kidney transplant recipients treated with CNI (calcineurin inhibitors)-free protocol versus kidney transplant recipients…
2015 American Transplant Congress
Associations Between Sirolimus Use and Outcomes After Liver Transplant for Hepatocellular Carcinoma
E. Yanik,¹ S. Chinnakotla,² A. Israni,^2,3 J. Snyder,^2,3 S. Gustafson,³ E. Engels.¹
¹Natl. Cancer Inst., Bethesda, MD; ²U. of Minnesota, Minneapolis, MN; ³Sci. Reg. of Transplant Recipients, Minneapolis, MN.
A growing fraction of U.S. liver transplants are being done for the indication of hepatocellular carcinoma (HCC). HCC recurrence after transplant remains a major concern…